Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › roxadustat

roxadustat

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of roxadustat

17 trials tracked of roxadustat: 11 in phase 3 or 4 and 9 with published results. The most-cited published study has 172 citations.

17Trials tracked
11Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 1 Phase 3 10 Phase 2 6
  1. Phase 3 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis Completed · 172 cited
  2. Phase 3 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. Completed · 133 cited
  3. Phase 3 A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis Completed · 111 cited
  4. Phase 3 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis Completed · 88 cited
  5. Phase 3 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Completed · 49 cited
  6. Phase 3 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa Completed · 49 cited
Show 11 more trials
  1. Phase 3 Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Completed · 49 cited
  2. Phase 3 Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants Completed · 49 cited
  3. Phase 4 A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD) Completed · 7 cited
  4. Phase 3 Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants Completed
  5. Phase 3 Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants Completed
  6. Phase 2 Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia Completed
  7. Phase 2 Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia Completed
  8. Phase 2 Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease Completed
  9. Phase 2 Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis Completed
  10. Phase 2 Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis Completed
  11. Phase 2 Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease
Drug Pipeline Meta-analysis
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease Roxadustat Linked to Higher Risk of Blood Clots in Kidney Patients
This systematic review and meta-analysis of 11,418 adults with chronic kidney disease found that roxadustat is associated with higher odds o…
A review of over 11,000 patients suggests roxadustat may increase the risk of blood clots and death for those with chronic kidney disease.
Frontiers Jun 13, 2026
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients
Nephrology Meta-analysis
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients Roxadustat Boosts Hemoglobin in Peritoneal Dialysis Patients
This systematic review and meta-analysis of 607 patients receiving peritoneal dialysis found that roxadustat significantly increased hemoglo…
A review of 607 patients on peritoneal dialysis finds roxadustat raises hemoglobin and iron levels while lowering hepcidin.
May 27, 2026
HIF-PHIs alter lipid profiles in CKD patients but show no cardiovascular mortality difference
Nephrology Meta-analysis
HIF-PHIs alter lipid profiles in CKD patients but show no cardiovascular mortality difference New drugs for kidney disease patients show lower bad cholesterol but no safety risks found in big study
This systematic review and meta-analysis of 12,155 CKD patients found that HIF-PHIs significantly reduced LDL-C, total cholesterol, and trig…
A large review of kidney disease patients found that a specific new drug lowered bad cholesterol levels. However, it did not cause heart att…
May 7, 2026